Tocilizumab: A new anti-rheumatic drug

Saudi Pharmaceutical Journal

Volumn 18, Issue 4, 2010, Pages 257-259

  Abou Auda, Hisham S ^a   Sakr, Walid ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Tocilizumab

Indexed keywords

CYCLOSPORIN; DEXTROMETHORPHAN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; TOCILIZUMAB; WARFARIN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; RHEUMATOID ARTHRITIS;

EID: 84755161021     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2010.07.009     Document Type: Article

References (13)

1. Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. Lancet 2008, 371.
2. European Medicines Agency (EMEA), 2009. Evaluation of Medicines for Human Use [Assessment Report for RoActemra], Doc. Ref.: EMEA/26276/2009, Procedure No. EMEA/H/C/000955.
3. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Research & Therapy 2006, 8(Suppl. 2):S3.
4. Haghighi A., Safari A. Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease. Medical Hypothesis 2008, 71:156-157.
5. Kato A., Matsuo S., Takai Hirotake., Uchiyama Y., Mihara M., Suzuki M. Early effects of Tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Experimental and Molecular Pathology 2008, 84:262-270.
6. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Research & Therapy 2006, 8(Suppl. 2):S2.
7. Lipsky P. Interleukin-6 and rheumatic diseases. Arthritis Research & Therapy 2006, 8(Suppl. 2):S4.
8. Mihara M., Kasutani K., Okazaki M., Nakamura A., Kawai S., Sugimoto M., Matsumoto Y., Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. International Immunopharmacology 2005, 5:1731-1740.
9. Smolen J., Maini R. Interleukin-6: a new therapeutic target. Arthritis Research & Therapy 2006, 8(Suppl. 2):S5.
10. Smolen J., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., Woodworth T., Alten R. Effect of interleukin-6 receptor inhibition with Tocilizumab in patients with rheumatoid arthritis a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
11. Stubenrauch K., Wessels U., Vogel R., Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Analytical Biochemistry 2009, 390:189-196.
12. Wang D., He J. Tocilizumab as a potential treatment in Schnitzler syndrome. Medical Hypotheses 2009, 72:473-483.
13. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.